(NASDAQ: DFTX) Definium Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.72%.
Definium Therapeutics's earnings in 2026 is -$237,543,000.On average, 18 Wall Street analysts forecast DFTX's earnings for 2026 to be -$233,064,809, with the lowest DFTX earnings forecast at -$273,626,745, and the highest DFTX earnings forecast at -$195,829,409. On average, 17 Wall Street analysts forecast DFTX's earnings for 2027 to be -$196,254,769, with the lowest DFTX earnings forecast at -$280,258,006, and the highest DFTX earnings forecast at -$60,695,665.
In 2028, DFTX is forecast to generate -$87,689,694 in earnings, with the lowest earnings forecast at -$240,492,257 and the highest earnings forecast at $344,705,568.